Raza Ahmad, Estepa Adrian, Chan Vincent, Jafar Munnam S
Internal Medicine, Abington Hospital-Jefferson Health, Abington, USA.
Internal Medicine, Abington Hospital, Jefferson Health, Abington, USA.
Cureus. 2020 Jun 3;12(6):e8429. doi: 10.7759/cureus.8429.
Acute renal failure remains a significant concern in all patients with the coronavirus disease 2019 (COVID-19) infection. Management is particularly challenging in critically ill patients requiring intensive care unit (ICU) level of care. Supportive care in the form of accurate volume correction and avoiding nephrotoxic agents are the chief cornerstone of the management of these patients. The pathophysiology of acute renal failure in COVID-19 is multifactorial, with significant contributions from excessive cytokine release. Gaining a better insight into the pathophysiology of renal failure will hopefully help develop more directed treatment options. A considerable number of these patients deteriorate despite adequate supportive care owing to the complexity of the disease and multi-organ involvement. Renal replacement therapy is used for a long time in critically ill septic patients who develop progressive renal failure despite adequate conservative support. Timing and choice of renal replacement therapy in critically ill COVID-19 patients remains an area of future research that may help decrease mortality in this patient population.
急性肾衰竭仍是所有2019冠状病毒病(COVID-19)感染患者的一个重大问题。对于需要重症监护病房(ICU)级别护理的重症患者,管理尤其具有挑战性。以精确的容量校正和避免使用肾毒性药物形式的支持性护理是这些患者管理的主要基石。COVID-19中急性肾衰竭的病理生理学是多因素的,过度的细胞因子释放起了重要作用。更好地了解肾衰竭的病理生理学有望有助于开发更有针对性的治疗方案。由于疾病的复杂性和多器官受累,相当一部分患者尽管接受了充分的支持性护理仍会恶化。肾替代疗法长期用于尽管接受了充分的保守支持仍发生进行性肾衰竭的重症脓毒症患者。重症COVID-19患者肾替代疗法的时机和选择仍是未来研究的一个领域,这可能有助于降低该患者群体的死亡率。